Besides their role in desensitization, b-arrestin 1 and 2 promote the formation of signaling complexes allowing G protein-coupled receptors (GPCR) to signal independently from G proteins. Here we show that lithium, a pharmacological agent used for the management of psychiatric disorders such as bipolar disorder, schizophrenia, and depression, regulates Akt/ glycogen synthase kinase 3 (GSK3) signaling and related behaviors in mice by disrupting a signaling complex composed of Akt, b-arrestin 2, and protein phosphatase 2A. When administered to b-arrestin 2 knockout mice, lithium fails to affect Akt/GSK3 signaling and induce behavioral changes associated with GSK3 inhibition as it does in normal animals. These results point toward a pharmacological approach to modulating GPCR function that affects the formation of b-arrestin-mediated signaling complexes.
INTRODUCTION
The scaffolding proteins b-arrestin 1 and b-arrestin 2 (bArr2) have been traditionally associated with the termination of G protein-coupled receptor (GPCR) signaling and with receptor desensitization (Ferguson et al., 1996; Lohse et al., 1989) . Following stimulation, GPCRs are rapidly phosphorylated by members of a family of GPCR kinases (GRKs) (Premont and Gainetdinov, 2007) . The phosphorylation of receptors by GRKs leads to b-arrestin recruitment, resulting in the uncoupling of the receptors from G proteins and GPCR internalization. However, evidence obtained from cell culture systems (Luttrell et al., 1999; Ahn et al., 2004) has shown that b-arrestins also act as scaffolds for the formation of signaling protein complexes allowing GPCRs to signal independently from G proteins.
We have recently shown in vivo that the Akt/glycogen synthase kinase 3 (GSK3) signaling cascade can be regulated by a signaling complex scaffolded by bArr2 (Beaulieu et al., 2005 (Beaulieu et al., , 2007a . Akt is a serine/threonine kinase regulated by phosphatidylinositol kinase (PI3K)-mediated signaling. Activation of Akt involves phosphorylation of a regulatory threonine residue (Thr308) by phosphatidylinositol-dependent kinase 1 (PDK1) and additional phosphorylation of Ser473 by the PDK2/TORC2 kinase (Alessi and Cohen, 1998; Jacinto et al., 2006) . In turn, activated Akt phosphorylates GSK3b, a constitutively active kinase, on the Ser 9 residue and renders it inactive (Cross et al., 1995) .
Stimulation of the dopamine (DA) D2 receptor (D2R), a prototypical GPCR, in the mouse striatum results in Akt inactivation and concomitant activation of GSK3b (Beaulieu et al., 2004 (Beaulieu et al., , 2006 (Beaulieu et al., , 2007b . Importantly, bArr2 is essential for the regulation of Akt and GSK3 by D2R. Activation of this GPCR by tonic DA and/or dopaminergic drugs leads to the formation of a signaling complex composed of Akt, bArr2, and the protein phosphatase 2A (PP2A), which dephosphorylates/inactivates Akt, as demonstrated pharmacologically (Beaulieu et al., 2005) . Furthermore, regulation of the Akt/GSK3 signaling by bArr2 plays an important role for the expression of behavioral responses to DA or drugs such as amphetamine, which act on DA neurotransmission (Beaulieu et al., 2005; Gainetdinov et al., 2004) .
Modulation of Akt/GSK3 signaling by lithium also antagonizes the development of DA-dependent behaviors in rodents (Beaulieu et al., 2004; Cox et al., 1971) . Lithium is commonly used in the management of mood disorders along with drugs targeting central monoaminergic transmission (Phiel and Klein, 2001; Valenstein et al., 2006) . Although multiple molecular targets of lithium have been identified (Berridge et al., 1989; Klein and Melton, 1996) , the mechanisms by which this agent exerts its therapeutic actions are still not well understood (Phiel and Klein, 2001) . Among other actions, lithium can inhibit GSK3 either directly (Klein and Melton, 1996) or indirectly by increasing its Akt-mediated inhibition (Beaulieu et al., 2004; Chalecka-Franaszek and Chuang, 1999; De Sarno et al., 2002) . Furthermore, pharmacological or genetic inhibition of GSK3b in rodents recapitulates some of the effects of lithium on behavior (Beaulieu et al., 2004; Gould et al., 2004; O'Brien et al., 2004) , whereas overexpression of this kinase in mice reproduces behavioral correlates of hyperactivity and mania (Prickaerts et al., 2006) .
Here we provide evidence for the involvement of the Akt: bArr2:PP2A signaling complex in the pharmacological actions of lithium in vivo, thus indicating that b-arrestin signaling complexes may represent a target for drug intervention aimed at the regulation of GPCR signaling.
RESULTS

Regulation of Akt/GSK3 Phosphorylation by Lithium Requires b-arrestin 2
To investigate the actions of lithium on the Akt:bArr2:PP2A signaling complex, wild-type (WT) and bArr2-KO mice were treated with lithium under conditions shown to activate brain Akt and affect behavior without toxicity in rodents (Beaulieu et al., 2004) . (A-C) Western blot (A) and densitometric analysis (B and C) of relative levels of phospho-Thr308-Akt and phospho-Ser9-GSK3b in extracts prepared from the striatum of WT or bArr2-KO mice 30 min after injection of LiCl (200 mg/kg, i.p.). Representative western blots show results obtained from two separate striatal extracts prepared from different mice for each group. For densitometric analysis 10 mice per group were used. (D) Densitometric analysis of relative levels of phospho-Ser9-GSK3b from western blots prepared from the striatum of WT (C57BL/6) mice treated with LiCl (50 or 100 mg/kg, i.p.) (n = 5 mice per group). (E) Basal phosphorylation of Akt and GSK3b in the striatum of bArr2-KO mice as compared to WT littermates (n = 5 per group). (F) Basal levels of Akt and GSK3b in striatal extract from drug-naive bArr2-KO and WT littermates (n = 5 mice per group). (G-J) Western blots (G and I) and densitometric analysis (H and J) of phospho-Thr308-Akt and phospho-Ser9-GSK3b in the striatum of WT or bArr2-KO mice 30 min after ICV injection of either vehicle or 5 ml of a 5 mM pbV (phen) solution. Total kinase levels in extracts were used as loading controls for measurement of phospho-protein levels while b-actin was used as a loading control in (F). Data are means ± SEM; *p % 0.05, ***p % 0.005, two-tailed Student's t test.
Administration of lithium (200 mg/kg i.p.), which produces brain concentrations of lithium of $1 mM (see Table S1 available online), to WT mice increased striatal levels of phospho-Akt and phospho-GSK3b ( Figures 1A-1C) . A similar increase of striatal GSK3b phosphorylation in WT mice was also evident with 100 mg/kg lithium ( Figure 1D ). In contrast, administration of lithium to bArr2-KO mice resulted in a minor reduction in striatal phosphoAkt and did not affect phospho-GSK3b levels ( Figures 1A-1C) .
Comparison of basal phospho-Akt and phospho-GSK3b levels in WT and bArr2-KO mice showed that a lack of bArr2 markedly increased the phosphorylation of these kinases without changing their overall levels ( Figures 1E and 1F ). These data are consistent with a contribution of bArr2 in the regulation of Akt by PP2A in mice having a normal dopaminergic tone (Beaulieu et al., 2005) . However, since bArr2 may affect many signaling pathways it is important to verify if it is still possible to increase the phosphorylation of Akt and GSK3b in bArr2-KO mice in response to PI3K signaling. To assess this, we used bis peroxovanadium 1,10-phenanthroline (bpV(phen)), a potent activator of PI3K signaling that enhances Akt and GSK3b phosphorylation in cells (Lavoie et al., 1999) . As shown ( Figures 1G-1J ), intracerebroventricular (icv) injection of bpV(phen) to either WT or bArr2-KO mice resulted in an increased phosphorylation of both Akt and GSK3b in the striatum of these mice. Taken together these data indicate that bArr2 is essential for the regulation of Akt and GSK3b phosphorylation by lithium but not by PI3K-mediated signaling.
GSK3b and b-arrestin 2 Mediate Behavioral Effects of Lithium
We then proceeded to investigate the contribution of bArr2 to the acute behavioral responses to lithium. Inhibition of locomotor activity in a novel environment, a documented behavioral effect of acute lithium treatment (Beaulieu et al., 2004) , was evaluated in WT and bArr2-KO mice. In nonhabituated WT mice, LiCl (100 or 200 mg/kg, i.p.) caused a dose-dependent inhibition of horizontal activity ( Figure 2A ). As previously reported (Beaulieu et al., 2005) , bArr2-KO mice displayed reduced horizontal activity as compared to WT littermates when placed in a novel environment ( Figure 2A ). However, administration of LiCl to bArr2-KO mice did not affect horizontal activity (Figure 2A ). LiCl was also administered by ICV injection under conditions known not to elicit peripheral responses to lithium in rodents (Smith, 1980). In line with results obtained following systemic lithium administration, ICV lithium injections provoked a marked reduction of locomotor activity in WT mice while having no effect in bArr2-KO mice ( Figure 2B ), thus demonstrating that bArr2-dependent behavioral effects of lithium are centrally mediated.
To assess the involvement of GSK3b in this action of lithium on behavior, GSK3b haploinsufficient mice (gsk3b (Hoeflich et al., 2000) were also tested. As shown ( Figure 2C ), vehicle-treated gsk3b +/À and WT littermates exhibited comparable locomotor activity in a novel environment. However, administration of LiCl (100 mg/kg i.p.) had a more pronounced effect on locomotion in gsk3b +/À than in WT mice, thus supporting the involvement of GSK3b inhibition in the locomotor-suppressing action of lithium.
To further examine the contribution of GSK3b, we used direct pharmacological inhibition of GSK3 with the blood brain barrierpermeable GSK3b inhibitor thiadiazolidinone (TDZD-8) (Beaulieu et al., 2004; Martinez, 2006) . Administration of TDZD-8 (30 mg/kg i.p.) to WT mice led to a reduction of novelty-induced horizontal activity comparable to that observed following lithium administration ( Figure 2D ). To address the possibility of a nonspecific toxic action of TDZD-8 we also administered this drug to habituated animals and monitored activity. Importantly, the effect of TDZD-8 on locomotion was specific to novelty-induced locomotor activity since this drug had no effect in habituated mice ( Figure 2E ).
Lithium can inhibit GSK3b both directly (Klein and Melton, 1996) and indirectly by enhancing Akt activity (Beaulieu et al., 2004; Chalecka-Franaszek and Chuang, 1999) . To address the relative contributions of these mechanisms we treated bArr2-KO mice with TDZD-8 to evaluate whether direct inhibition of GSK3b can affect novelty-induced locomotor activity in these mice. TDZD-8 (30 mg/kg, i.p.) produced a reduction of horizontal activity in bArr2-KO mice resulting in activity levels comparable to those obtained with this drug in WT mice ( Figure 2D ). This indicates that novelty-induced locomotor activity can be further suppressed by a direct inhibition of GSK3 in mice lacking bArr2. Thus, the absence of a lithium effect on locomotion in bArr2-KO mice likely reflects a disruption of the indirect, Akt-mediated, inhibitory action of lithium on GSK3b ( Figure 2F ).
Apart from their action on locomotion, lithium and GSK3 inhibitors also have effects on behavioral paradigms used to evaluate the action of antidepressants in mice (Gould et al., 2004; O'Brien et al., 2004) . Reduction of immobility times in the tail suspension test is a paradigm commonly used to evaluate ''antidepressantlike'' effects of drugs in rodents (Crowley et al., 2004) . A first set of tests showed that acute administration of different doses of LiCl reduces immobility in WT mice (Figures 3A and 3B) and that GSK3b haploinsufficiency phenocopies this behavioral effect ( Figure 3B ). Furthermore administration of lithium to gsk3b +/À mice resulted in more pronounced reduction of immobility than in WT littermates ( Figure 3B ), thus supporting a role for GSK3b inhibition in the ''antidepressant-like'' action of lithium.
To further establish the involvement of bArr2 in behavioral responses to lithium we performed the tail suspension test following acute LiCl administration to bArr2-KO mice. As shown ( Figure 3A ), while LiCl (75 or 100 mg/kg i.p.) caused pronounced reductions of immobility time in WT mice, these same treatments failed to induce significant changes in bArr2-KO mice.
Measurement of the latency to cross from a dark compartment to an illuminated one in the dark-light emergence test is a simple behavioral assay used to assess the anxiolytic efficacy of antidepressants and anxiolytics in rodents (Crawley and Goodwin, 1980; Weisstaub et al., 2006) . As shown in Figure 3C , acute lithium treatment markedly reduces the latency to cross in WT animals. Furthermore, pharmacological inhibition of GSK3b with TDZD-8 exerts a similar effect in these mice, thus suggesting a contribution of GSK3-mediated signaling events in this effect of acute lithium ( Figure 3D ). However, acute administration of LiCl (75 mg/kg) had no effect on this behavioral paradigm in bArr2-KO mice ( Figure 3C ). Taken together, these observations demonstrate that bArr2 is an important determinant of the regulation of behavior by acute lithium and suggest that this compound may exert part of its actions by interfering with the regulation of Akt and GSK3b by the Akt:bArr2:PP2A signaling complex.
Lithium Disrupts the Akt:bArr2:PP2A Signaling Complex In Vitro The observation that immunoprecipitation of Akt from striatal extracts led to a coimmunoprecipitation of the endogenous catalytic C subunit of PP2A in WT mice but not in bArr2-KO mice ( Figure 4A ) indicates that bArr2 is an essential scaffold for the interaction of these two signaling proteins in the mouse striatum (Beaulieu et al., 2005) . We next investigated the effect of lithium on the stability of the Akt:bArr2:PP2A signaling complex. In a first set of in vitro experiments, Akt immunoprecipitations were performed using striatal extracts from nontreated WT mice with lysis buffers containing various lithium concentrations (0 to 10 mM). These experiments revealed a destabilization of the Akt:bArr2 and Akt:PP2A C subunit interactions in lysis buffers containing LiCl concentrations greater than 0.5 mM ( Figure 4B ), thus suggesting that at these concentrations lithium can destabilize preassembled Akt:bArr2:PP2A signaling complexes in vitro.
To further test this possibility, immunoprecipitations using antibodies directed against the B subunit of PP2A were carried out in the presence of 1 mM LiCl. PP2A is a multimeric protein complex composed of a structural A subunit, a catalytic C subunit, and one of a variety of targeting B subunits (Janssens and Goris, 2001) . Consistent with previous results, lithium prevented the immunoprecipitation of Akt with the targeting B subunit of PP2A ( Figure 4C ). In contrast, it did not affect the interaction of PP2A B and C subunits, thus indicating that lithium disrupts the Akt: bArr2:PP2A signaling complex without affecting the integrity of PP2A.
To rule out the possibility that increased salt concentrations may nonspecifically affect the integrity of the complex, immunoprecipitations were carried out in the presence of higher concentrations of various chloride salts. As shown ( Figure 4D ), in contrast to LiCl (20 mM), other salts, KCl (20 mM), NaCl (20 and 100 mM), CaCl 2 (20 mM), or MgCl 2 (20 mM) did not markedly affect the bArr2-mediated interaction of Akt and PP2A, thus suggesting a selective role of lithium in destabilizing the Akt: bArr2:PP2A complex. (H) Salt-dependent coimmunoprecipitation of purified GST-bArr2 recombinant protein with recombinant phospho-Akt1. Purified proteins were incubated in interaction buffers containing either no added salts, MgCl 2 (20 mM), LiCl (50 mM), or a combination of these salts. All experiments were replicated at least three times.
Disruption of the Akt:bArr2:PP2A Complex by Lithium In Vivo To examine the effect of lithium on the Akt:bArr2:PP2A complex in vivo, we performed coimmunoprecipitations using a lithium-free lysis buffer and striatal extracts obtained from LiCl (200 mg/kg, i.p.) or vehicle-treated WT mice at 30 min post-injection. As shown (Figure 4E ), lithium treatment prevented the bArr2-dependent interaction of Akt and PP2A, indicating that lithium also destabilizes the Akt:bArr2:PP2A signaling complex in vivo.
Lithium/Magnesium Competition Destabilizes the Akt:bArr2 Interaction It has been suggested that lithium may exert some of its pharmacological effects by competing with magnesium, a cofactor of multiple enzymes including kinases such as GSK3 (Birch, 1974; Ryves and Harwood, 2001) . To explore the possible involvement of a lithium/magnesium competition on the destabilization of Akt:bArr2:PP2A complexes, coimmunoprecipitations were carried out using lysis buffers containing both lithium and various other cations. Remarkably, MgCl 2 but not NaCl or KCl interfered with the disruption of preassembled Akt:bArr2:PP2A complexes by LiCl in vitro ( Figure 4F ). We then used purified recombinant proteins to examine the impact of lithium and magnesium on the Akt:bArr2 interaction. As previously shown (Beaulieu et al., 2005) , purified recombinant phospho-Akt1 directly and specifically interacts with a recombinant bArr2 tagged with glutathione S-transferase (GST) ( Figure 4G ). Purified GST-bArr2 was incubated with the recombinant Akt1 in salt-free buffer or in buffers containing either MgCl 2 , LiCl, or both salts. Immunoprecipitation of recombinant Akt1 following these incubations revealed that while Akt1 can form a complex with the recombinant GST-bArr2 in the presence of magnesium (20 mM), this interaction fails to occur in salt-free buffer ( Figure 4H ). Moreover, addition of LiCl (50 mM) to the buffer containing magnesium also prevents the interaction of Akt and GST-bArr2 ( Figure 4H ). These results indicate that magnesium is a cofactor for the interaction of Akt and bArr2. Furthermore, this suggests that lithium competition with magnesium can affect not only enzymatic activity but also the stability of higher-order protein complexes, thus providing a potential mechanism for the destabilization of the Akt:bArr2:PP2A complex by lithium.
No Effect of Lithium on Other b-arrestin 2-Mediated Functions
To address the general effect of lithium on bArr2-mediated GPCR desensitization and signaling, we tested whether it would interfere with the formation and cellular functions of other bArr2 protein complexes in vitro, in a cellular system, and in vivo. In a first set of experiments, a recombinant Flag-bArr2 was expressed in human embryonic kidney cells (HEK293) and endogenous cellular proteins were coimmunoprecipitated with the recombinant bArr2 in the presence or absence of lithium. As shown ( Figure 5A ), addition of LiCl (20 mM) to the lysis buffer did not destabilize the interactions of Flag-bArr2 with the known bArr2 interaction partners (DeWire et al., 2007) clathrin, MDM2, and Raf1. Furthermore, although the interactions of extracellular signal-regulated kinase 1 (ERK1) and ERK2 with bArr2 were somewhat reduced by lithium, these interactions were still clearly detectable in buffers containing lithium concentrations 20 times greater then those sufficient to disrupt the Akt: bArr2:PP2A signaling complex.
We then analyzed two well-documented bArr2 functions in HEK293 cells-the stimulation of ERK2 following prolonged angiotensin receptor stimulation (Ahn et al., 2004) and the recruitment of green fluorescent protein (GFP) tagged bArr2 to GPCRs during receptor desensitization (Barak et al., 1997) . Despite its moderate effect on the interaction of bArr2 with ERK2, lithium at concentrations as high as 100 mM did not interfere with bArr2-mediated ERK2 stimulation ( Figure 5B ). Furthermore, lithium had no significant effect on the recruitment of bArr2-GFP to either angiotensin or D2 receptors upon stimulation in HEK293 cells ( Figures 5C and 5D) .
Finally, potential changes in receptor sensitivity in response to lithium in vivo were assessed indirectly by measuring D2R coupling to G proteins in brain tissue. Freshly dissociated striatal pieces were pre-exposed to lithium (10 mM) in presence or absence of millimolar concentrations of quinpirole for 15 min to allow for activation and desensitization of D2Rs . After this pre-exposure period, membranes were prepared and assessed for [
35 S]GTPgS binding following D2R stimulation with increasing concentrations of quinpirole ( Figure 5E ). Under these conditions, pretreatment with quinpirole completely abolished agonist-stimulated binding of [ 35 S]GTPgS to membrane, suggesting that D2Rs had been desensitized during pretreatment. Importantly, cotreatment of striatal tissue with lithium had no effect on agonist-stimulated binding of [ 35 S]GTPgS to membrane prepared from either quinpirole-treated or nontreated tissue, thereby indicating that the effect of lithium on the formation of the Akt:bArr2:PP2A complex does not extend to all of bArr2 functions, such as receptor desensitization.
b-arrestin 2 Is Essential for Responses to Chronic Lithium
Since lithium is used chronically for therapy, we investigated the effect of chronic lithium treatment in WT and bArr2-KO animals. Mice were given lithium for 15 days following a protocol known to produce clinically relevant serum lithium levels (see Supplemental Experimental Procedures and Table S1 ). Analysis of striatal extracts from WT mice confirmed that chronic lithium treatment enhances Akt and GSK3b phosphorylation in neuronal tissues ( Figures 6A and 6B) . However, chronic lithium administration did not influence Akt and GSK3b phosphorylation in bArr2-KO mice ( Figures 6A and 6B) , thus showing that bArr2 is also essential for the regulation of these kinases following chronic lithium treatment.
b-catenin is a component of the Wnt signaling pathway, which is degraded following its phosphorylation by GSK3 (Orford et al., 1997) . Interestingly, chronic lithium treatment producing clinically relevant serum levels also increases brain b-catenin levels in rodents, thus providing a biochemical marker for the ability of lithium to modulate GSK3 activity (De Ferrari et al., 2003) . Furthermore, overexpression of b-catenin has recently been shown to phenocopy some behavioral outcomes of chronic lithium in mice (Gould et al., 2007) . To examine the possible contribution (AT1aR) were stimulated with 100 nM angiotensin II for 60 min in presence or absence of LiCl (10 or 100 mM in culture media for 12 hr prior and through the test) and assayed for ERK2 phosphorylation (Thr202 and Tyr204) using western blot. (C and D) Lithium does not affect bArr2 recruitment to activated GPCRs in HEK293 cells. Cells stably expressing the AT1aR (C) were transfected with bArr2-GFP vectors and treated for 30 min with angiotensin II (100 nM) in the presence or absence of lithium (10 mM in culture media for 12 hr prior and through the test). Alternatively (D), cells were cotransfected with bArr2-GFP and D2L DA receptor expression vectors and treated for 30 min with the D2 receptor agonists apomorphine (20 mM) or bromocryptine (20 mM) in the presence or absence of lithium. Internalization of receptors and bArr2-GFP recruitment was observed by confocal microscopy. White arrows indicate complexes of AT1aR:bArr2-GFP and D2LR:bArr2-GFP, respectively, in internalized vesicle (C) and plasma membrane puncta (D) representative of class A and B GPCRs (Oakley et al., 2000) ; Scale bar: 10 mm. of bArr2 in the development of biochemical changes induced by chronic lithium treatment, we measured striatal b-catenin levels in bArr2-KO and WT littermates following chronic lithium administration. As might be expected, chronic treatment of WT mice with lithium resulted in a marked increased of striatal b-catenin levels ( Figures 6C and 6D ). In contrast, this same treatment had no effect on the level of b-catenin in bArr2-KO mice ( Figures 6C and 6D) , indicating the involvement of bArr2 in the regulation of b-catenin by lithium.
To assess the role of bArr2 in the behavioral effects of chronic lithium, we then tested chronically treated WT and bArr2-KO mice in the tail suspension and dark-light emergence tests. As shown (Figures 6E and 6F ), chronic lithium administration had a clear effect on both of these behavioral paradigms in WT mice. However, lithium was not effective in either of these tests in bArr2-KO mice ( Figures 6E and 6F ) thereby providing additional evidence for the involvement of the Akt:bArr2:PP2A signaling complex in the regulation of Akt/GSK3 signaling and related behaviors in response to acute and chronic lithium treatment.
DISCUSSION
The identification of G protein-independent GPCR signaling mechanisms has introduced the notion that GPCRs can signal simultaneously through distinct effector systems mediating subsets of their actions (Beaulieu et al., 2005; Rajagopal et al., 2006) . Consequently, direct targeting of b-arrestin-mediated signaling represents an appealing avenue for the development of drugs acting on GPCR functions that may promote desired therapeutic effects while avoiding undesired side effects associated with the regulation of other signaling modalities (Beaulieu et al., 2007a; DeWire et al., 2007) . The results presented here provide direct in vivo evidence that lithium exerts some of its biochemical and behavioral effects by interfering with a b-arrestin signaling complex involved in the regulation of Akt and GSK3b (Figure 7) .
Under conditions compatible with its effects on mouse behavior, lithium inhibits GSK3 indirectly by activating Akt (Beaulieu et al., 2004; De Sarno et al., 2002) . In living cells, overall Akt activity results from an equilibrium between its phosphorylation/activation and dephosphorylation/inactivation (Figure 7 ). Here we show that by disrupting the formation of the Akt: bArr2:PP2A signaling complex that normally promotes Akt dephosphorylation (Beaulieu et al., 2005) , lithium shifts this equilibrium toward the activated state, thereby resulting in increased phosphorylation/inactivation of GSK3b (Figure 6 ). In bArr2-KO mice that are unable to scaffold this signaling complex, lithium fails to activate Akt, thus leading to a loss of indirect inhibition of GSK3b by lithium and to a disruption of behavioral responses to this pharmacological agent.
Our results identify the destabilization of b-arrestin-mediated signaling complexes as a mechanism of action for a therapeutically effective drug, thereby providing an avenue for the development of pharmacological agents acting on GPCR signaling. Notably, the disruption of the Akt:bArr2:PP2A signaling complex occurs within a range of lithium concentrations (0.5 to 1.0 mM) that is close to its clinically effective serum levels. This suggests that lithium may exert some of its therapeutic action by regulating Akt/GSK3 signaling through disruption of a b-arrestin complex (Figures 4 and 7) . Although lithium is a direct inhibitor of GSK3 (Klein and Melton, 1996) , the relevance of this effect to Western blot and densitometric analysis of relative levels of phospho-Thr308 Akt (A) and phospho-Ser9-GSK3b (B) in extracts prepared from the striatum of WT or bArr2-KO mice following chronic lithium treatment (0.12% in drinking water for 15 days). Representative western blots show results obtained from separate striatal extracts prepared from two individual mice. For densitometric analysis, 10 mice per group were used. Total kinase levels in extracts were used as loading controls for measurement of relative phospho-protein levels. (C and D) Western blot and densitometric analysis of relative levels of b-catenin in extracts prepared from the striatum of WT or bArr2-KO mice following chronic lithium treatment (n = 5 mice per group). b-actin was used as a loading control. (E) Tail suspension test in WT or bArr2-KO mice following chronic lithium treatment. Behavior was scored as time spent in immobility (s) for the whole duration of the test (6 min) (n = 16-24 mice per group). (F) Dark-light emergence test in WT and in bArr2-KO mice following chronic lithium treatment. Behavior was scored as the latency to cross from the dark to the light compartment of the test chamber (n = 8 mice per group). Data are means ± SEM; ***p % 0.005; two-tailed Student's t test was used for analysis of western blots. One-way ANOVA with Bonferroni-corrected pairwise comparisons was used for analysis of behavioral data.
its therapeutic action has remained unclear mostly because of the high K i of lithium for this kinase (Phiel and Klein, 2001) . However lithium also inhibits GSK3 indirectly through Akt activation (Beaulieu et al., 2004; Chalecka-Franaszek and Chuang, 1999) . Multiple lines of in vivo evidence also support a role for Akt/ GSK3 signaling in the regulation of the amyloid precursor protein, tau, and b-catenin by lithium (Gould et al., 2007; O'Brien et al., 2004; Phiel et al., 2003) . Furthermore, lithium affects the regulation of the circadian clock by GSK3 (Yin et al., 2006) and inhibition of GSK3b activity in the brain has been shown to reproduce behavioral correlates of lithium action (Beaulieu et al., 2004; Gould et al., 2004; O'Brien et al., 2004) .
Additional lines of evidence have also underscored the potential role of Akt/GSK3 signaling as a common molecular signal integrator and therapeutic target for different classes of psychiatric drugs (Beaulieu, 2007) . For instance, antidepressants as well as typical and atypical antipsychotics have been shown to increase GSK3b phosphorylation in mouse brain (Emamian et al., 2004; Li et al., 2004 Li et al., , 2007 . Interestingly, apart from its use in the management of mood disorders, lithium is clinically used to enhance the action of atypical antipsychotics and antidepressants in poorly responsive subjects (Valenstein et al., 2006) . Identification of the Akt:bArr2:PP2A signaling complex as a molecular target of lithium thus provides a mechanism by which this pharmacological agent may enhance the actions of other drugs acting through Akt/GSK3 signaling by preventing the inhibition of Akt by PP2A.
The evidence presented here provides a biochemical mechanism that reconciles the effect of therapeutically effective lithium concentrations with its action on Akt/GSK3 signaling. Furthermore, the discrepancy between the effect of lithium and TDZD-8 on locomotor activity in bArr2-KO mice (Figure 2) suggests that indirect bArr2-dependent inhibition rather than direct GSK3b inhibition by lithium mediates the effect of this agent, at least on this behavioral paradigm. However it would be naive to assume that lithium has a single mechanism of action, and it is plausible that other mechanisms, such as the inhibition of inositol monophosphatases (Berridge et al., 1989) , also contribute to the pleiotropic effects of this pharmacological agent on behavior. Furthermore while the action of lithium on Akt/GSK3 signaling is critical for at least some behavioral manifestations in animal models, the relevance of our findings to the action of lithium as a mood stabilizer in patients with bipolar disorder remains to be further established.
In conclusion we have shown that lithium exerts at least some of its behavioral effects through the disruption of a signaling complex composed of Akt, PP2A, and bArr2. Importantly, lithium destabilizes this complex without affecting other important functions of bArr2 such as GPCR desensitization. These observations provide a mechanism by which lithium can modulate Akt/ GSK3 signaling and associated behaviors. Identification of this mechanism of action for lithium may provide insight into the molecular mechanism of mood regulation and provide unexplored research avenues to understand devastating human disorders such as major depression and bipolar disorder. Furthermore, the results presented here indicate that a pharmacologically effective agent can exert its action by directly disrupting a bArr2 signaling complex rather than by interacting with a GPCR, thus providing direct in vivo evidence for an additional type of pharmacological intervention to regulate specific modalities of GPCR signaling. Future investigations of such mechanism may pave the way for the development of therapeutic agents not only for the management of psychiatric disorders but also for a host of other human pathologies involving the dysregulation of GPCR signaling. (B) Lithium destabilizes the signaling complex formed by Akt, bArr2, and PP2A, thereby enhancing Akt activity by reducing its dephosphorylation. In turn, increased Akt activity results in a greater inhibition of GSK3b. In bArr2-KO mice, lithium cannot act through this mechanism and GSK3b is not inhibited.
EXPERIMENTAL PROCEDURES
Experimental Animals bArr2-KO mice and gsk3b +/À were described previously Hoeflich et al., 2000) .
Drug Administration
For acute treatments, LiCl (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and injected (i.p.). For chronic treatments, LiCl was added to the drinking water for a period of 15 days at a concentration of 0.12%. TDZD-8 (Calbiochem, Cambridge, MA) was injected (i.p.) after suspension in a minimal amount of Tween and brought to volume with distilled water as described (Beaulieu et al., 2004) . The procedure for ICV injections has been described previously (Beaulieu et al., 2005) . Both LiCl and pbV (Phen) (Calbiochem) were prepared in sterile artificial CSF (CMA Microdyalisis, N. Chelmsford, MA).
Western Blot Analysis
Western blot analyses were performed as described (Beaulieu et al., 2004) . Samples were homogenized in boiling 1% SDS solution supplemented with 2 mM okadaic acid. Protein extracts (25 or 50 mg) were separated on 10% SDS/PAGE and transferred to nitrocellulose membranes. Blots were immunostained overnight at 4 C with primary antibodies. Immune complexes were detected using appropriate peroxidase-conjugated secondary antibodies along with a chemiluminescent reagent. 
Immunoprecipitations from Cells and Brain Tissue
Protein:Protein Interaction on Recombinant Proteins
The construct expressing GST-bArr2 recombinant proteins and the protocol used for GST protein production and affinity purification have been described previously (Beaulieu et al., 2005) . To evaluate the impact of different salts on the formation of the Akt:bArr2 protein complex, GST-bArr2 was produced in a recombinant bacterial system and purified by affinity purification. Purified GST-bArr2 was adjusted to a concentration of 1 mg/ml in ice-cold Tris-HCl (10 mM, pH 7.4) plus protease inhibitors. Recombinant GST-bArr2 (20 mg) was incubated for 8 hr at 4 C along with phospho-Akt1 (2 mg) in 1 ml of assay buffer (Tris-HCl [10 mM, pH7.4], okadaic acid [2 mM], and protease inhibitors) containing different concentrations of LiCl and MgCl 2 .
Measurement of bArr2 Function in Cells HEK293 cells were maintained and transfected as described (Marion et al., 2004) . Confocal microscopy was performed on Flag-AT1aR-tagged HEK293 cells transiently transfected with bArr2-GFP as described (Barak et al., 1997) . Alternatively cells were transiently transfected with vectors expressing bArr2-GFP and the human D2L dopamine receptor (Kim et al., 2001) . For lithium and receptor agonist treatments, cells were serum-starved overnight, exposed to LiCl (10 or 100 mM), and stimulated 5 min later with 100 nM angiotensin II, 20 mM apomorphine, or 20 mM bromocryptine for either 30 or 60 min.
Agonist-Stimulated [
35 S]GTPgS Binding Experiments were carried out as described . Briefly, tissue pieces were incubated in the presence or absence of 1 mM quinpirole and/or 10 mM LiCl in 1 ml of lysis buffer (20 mM HEPES [pH 7.4], 100 mM NaCl, 2 mM MgCl 2 , 1 mM EDTA, 1 mM DTT) per sample for 15 min at 37 C.
Samples were then placed on ice and homogenized. Homogenates were centrifuged at 1000 rpm for 10 min at 4 C. Supernatant was further centrifuged at 13,000 rpm for 30 min at 4 C. between 1 mM and 10 nM. Incubation mixture (total volume of 200 ml) was filtered through Brandel GF/B glass filters, washed three times with 10 mM Tris-HCl (pH 7.4), and bound radioactivity determined by liquid scintillation spectrometry.
Measurement of Locomotor Activity
Mice were injected with vehicle (10 ml/kg body weight, i.p.) or drug, placed into the open field, and monitored for 1 hr after injection. Locomotor activity was measured in terms of the total distance traveled (horizontal activity) as described (Beaulieu et al., 2004) .
Tail Suspension Test and Dark-Light Emergence Test
For the tail suspension test, mice were tested for 6 min in a tail suspension apparatus (Med-Associates, St. Albans, VT) as described (Crowley et al., 2004) . The dark-light box emergence test was performed for a duration of 5 min with mice initially placed at the center of the dark chamber, as described (Weisstaub et al., 2006; Welch et al., 2007) .
Statistical Analysis
The data are presented as means ± SEM. Data from western blot were analyzed by two-tailed t test or ANOVA; behavioral data were evaluated by t test or repeated-measures ANOVA or one-way ANOVA followed by Bonferroni-corrected pairwise comparisons. A p < 0.05 was considered significant. Detailed description of experimental procedures and materials are available as Supplemental Data.
Supplemental Data
Supplemental Data contain Experimental Procedures and one table and can be found with this article online at http://www.cell.com/cgi/content/full/ 132/1/125/DC1/.
